{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:01:43Z","timestamp":1780290103677,"version":"3.54.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although semaglutide is widely used due to its efficacy in glycemic control and weight reduction, cases of the associated adverse drug reactions (ADRs), including kidney injury, have gradually increased. This systematic review aimed to summarize reported cases and case series of semaglutide-associated renal injury and their clinical and laboratory features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Case reports and case series on ADRs associated with semaglutide published in English and Chinese were systematically retrieved using relevant keywords from PubMed\/MEDLINE, Web of Science, Embase, the Cochrane Library, and the Chinese National Knowledge Infrastructure (CNKI) database from database inception to October 31, 2025. Demographic characteristics, clinical information, ADRs, kidney-related laboratory tests, and outcomes were extracted. We used the Joanna Briggs Institute Critical Appraisal Checklist for Case Reports (JBI Case Report Checklist) to evaluate the quality of each included study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 20 cases (7 males and 13 females) from 18 studies were included after screening 1039 selected publications, with patient ages ranging from 29 to 83 years. Most patients received semaglutide via subcutaneous injection for weight loss or blood sugar reduction. Except for one case with unknown history, all patients had a pre-existing medical condition and were receiving concomitant medications. ADRs occurred at the standard recommended dose, ranging from 0.25 to 2.0 mg and included acute kidney injury (AKI), acute renal failure (ARF), and acute interstitial nephritis (AIN). Twelve cases were diagnosed through renal biopsy, and the remaining eight cases were diagnosed based on renal function parameters. The dosage varied from 0.25 to 2.0 mg per week. The majority of patients developed ADRs after multiple administrations. The clinical manifestations of the patients were diverse. Following treatment, 17 patients improved or recovered, outcomes were not reported in two patients, and one patient did not recover.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Semaglutide use may be associated with kidney damage, which may be irreversible. Clinicians should be cautious when prescribing semaglutide to individuals with underlying conditions and those receiving concomitant medications, and should ensure regular monitoring of kidney function after treatment initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1793349","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:19:03Z","timestamp":1780287543000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A systematic review of semaglutide-associated kidney injury case reports"],"prefix":"10.3389","volume":"13","author":[{"given":"Xian","family":"Xiu","sequence":"first","affiliation":[{"name":"Hebei Key Laboratory of Basic Medicine for Diabetes, The Second Hospital of Shijiazhuang, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-pan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Basic Medicine for Diabetes, The Second Hospital of Shijiazhuang, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Basic Medicine for Diabetes, The Second Hospital of Shijiazhuang, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Du","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Basic Medicine for Diabetes, The Second Hospital of Shijiazhuang, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Min","sequence":"additional","affiliation":[{"name":"Changjiang Community Health Service Center, High-Tech Industrial Development Zone, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Pang","sequence":"additional","affiliation":[{"name":"Changjiang Community Health Service Center, High-Tech Industrial Development Zone, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Basic Medicine for Diabetes, The Second Hospital of Shijiazhuang, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtao","family":"Liu","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Basic Medicine for Diabetes, The Second Hospital of Shijiazhuang, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhao","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Basic Medicine for Diabetes, The Second Hospital of Shijiazhuang, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zan-chao","family":"Liu","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Basic Medicine for Diabetes, The Second Hospital of Shijiazhuang, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Xia","family":"Feng","sequence":"additional","affiliation":[{"name":"The Fifth Hospital of Shijiazhuang","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.jacc.2018.07.071","article-title":"The changing landscape of diabetes therapy for cardiovascular risk reduction: JACC state-of-the-art review.","volume":"72","author":"Newman","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e65910","DOI":"10.7759\/cureus.65910","article-title":"Unveiling the potential role of Glucagon-Like Peptide-1 (GLP-1) receptor agonists in offering protection of the cardiovascular, renal, and neural systems: an updated narrative review.","volume":"16","author":"Rajagopal","year":"2024","journal-title":"Cureus."},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jcpt.13230","article-title":"A review of GLP-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once-weekly agents.","volume":"45","author":"Cornell","year":"2020","journal-title":"J Clin Pharm Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e89656","DOI":"10.7759\/cureus.89656","article-title":"Semaglutide and non-arteritic anterior ischemic optic neuropathy: a systematic review.","volume":"17","author":"Hidalgo Ramos","year":"2025","journal-title":"Cureus."},{"key":"B5","doi-asserted-by":"publisher","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide.","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"24103","DOI":"10.1038\/s41598-025-09807-0","article-title":"Efficacy and safety of GLP-1 agonists in the treatment of T2DM: a systematic review and network meta-analysis.","volume":"15","author":"Ren","year":"2025","journal-title":"Sci Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials.","volume":"45","author":"Aroda","year":"2019","journal-title":"Diab Metab."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.2147\/DDDT.S470826","article-title":"Clinical pharmacokinetics of semaglutide: a systematic review.","volume":"18","author":"Yang","year":"2024","journal-title":"Drug Des Devel Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-023-02096-9","article-title":"Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network.","volume":"23","author":"Garc\u00eda-Vega","year":"2024","journal-title":"Cardiovas Diabetol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with Type 2 diabetes.","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12974-025-03465-9","article-title":"Semaglultide targets Spp1(+) microglia\/macrophage to attenuate neuroinflammation following perioperative stroke.","volume":"22","author":"Li","year":"2025","journal-title":"J Neuroinflamm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1386542","DOI":"10.3389\/fendo.2024.1386542","article-title":"Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus.","volume":"15","author":"Rodr\u00edguez Jim\u00e9nez","year":"2024","journal-title":"Front Endocrinol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2465870","article-title":"Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.","author":"Alfehaid","year":"2025","journal-title":"Exp Opin Drug Safety"},{"key":"B15","doi-asserted-by":"publisher","first-page":"sfae250","DOI":"10.1093\/ckj\/sfae250","article-title":"Semaglutide-associated kidney injury.","volume":"17","author":"Begum","year":"2024","journal-title":"Clin Kidney J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.3390\/ijms25084346","article-title":"Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA Semaglutide (Ozempic) therapy for diabetes mellitus and obesity: a systematic literature review.","volume":"25","author":"Feier","year":"2024","journal-title":"Intern J Mol Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5144\/0256-4947.2025.129","article-title":"Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis.","volume":"45","author":"Safwan","year":"2025","journal-title":"Ann Saudi Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.endien.2024.03.012","article-title":"Acute pancreatitis due to different semaglutide regimens: an updated meta-analysis.","volume":"71","author":"Masson","year":"2024","journal-title":"Endocrinol Diab Nutr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1003583","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev."},{"key":"B20","volume-title":"\u00a9 Joanna Briggs Institute 2017 Critical Appraisal Checklist for Case Reports","author":"Martin","year":"2017"},{"key":"B21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1681\/ASN.20213210S1139c","article-title":"AKI induced by oral semaglutide leading to metformin-induced lactic acidosis.","volume":"32","author":"Halderman","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"100561","DOI":"10.1016\/j.xkme.2022.100561","article-title":"Semaglutide-Associated acute interstitial nephritis: a case report.","volume":"4","author":"Borkum","year":"2022","journal-title":"Kidney Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.eprac.2022.03.068","article-title":"Abstract #1161911: acute renal failure: a rare and uncommon side effect of semaglutide.","volume":"28","author":"Chaiban","year":"2022","journal-title":"Endocrine Practice."},{"key":"B24","first-page":"530","article-title":"GLP-1 analogue induced AKI.","volume":"115","author":"Kundu","year":"2022","journal-title":"Southern Med J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e00922","DOI":"10.14309\/crj.0000000000000922","article-title":"Progressive cholestasis and biliary cirrhosis after initiating oral semaglutide: report from the drug-induced liver injury network.","volume":"9","author":"Ma","year":"2022","journal-title":"ACG Case Rep J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"bvad114.716","DOI":"10.1210\/jendso\/bvad114.716","article-title":"Acute interstitial nephritis- a complication of semaglutide use.","volume":"7","author":"Hasan","year":"2023","journal-title":"J Endocrine Soc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5414\/cnp65380","article-title":"Hepatitis B infection as a possible cause of focal segmental glomerulosclerosis (FSGS).","volume":"65","author":"Herberth","year":"2006","journal-title":"Clin Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1681\/ASN.20233411S1426e","article-title":"A case of semaglutide-associated severe AKI in an immunocompromised patient.","volume":"34","author":"Patel","year":"2023","journal-title":"J Am Soc Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"A456","DOI":"10.1210\/jendso\/bvae163.873","article-title":"Ozempic - Oh no! acute renal failure associated with initiation of semaglutide.","volume":"8","author":"Barney","year":"2024","journal-title":"J Endocrine Soc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.4081\/itjm.2024.1694","article-title":"Semaglutide and kidney function: friends or enemies?","volume":"18","author":"Giofr\u00e8","year":"2024","journal-title":"Ital J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"omaf177","DOI":"10.1093\/omcr\/omaf177","article-title":"Semaglutide-associated drug-induced liver injury: a case report and review of the literature.","volume":"2025","author":"Kempster","year":"2025","journal-title":"Oxf Med Case Rep."},{"key":"B32","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1053\/j.ajkd.2024.01.151","article-title":"A unique case of semaglutide associated minimal change disease.","volume":"83","author":"Phillips","year":"2024","journal-title":"Am J Kidney Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1681\/ASN.2024jjazfwfy","article-title":"Semaglutide-Associated minimal change disease: a potential rare complication of a novel medication.","volume":"35","author":"Tan","year":"2024","journal-title":"J Am Soc Nephrol."},{"key":"B34","first-page":"835","article-title":"A case report of acute kidney injury caused by semaglutide in combination with multiple medications.","volume":"34","author":"Gu","year":"2025","journal-title":"Chin J Pharmacoepidemiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000543357","article-title":"Minimal change podocytopathy with coexistent thin glomerular basement membrane following exposure to semaglutide.","volume":"5","author":"Kovvuru","year":"2025","journal-title":"Glomerular Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e91679","DOI":"10.7759\/cureus.91679","article-title":"Unmasking semaglutide-induced gastroparesis: the dangers of rapid dose escalation in a diabetic patient.","volume":"17","author":"Singhal","year":"2025","journal-title":"Cureus."},{"key":"B37","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.xkme.2021.02.014","article-title":"Glucagon-like peptide-1 receptor agonists and the risk of acute kidney injury: alarming, or not?.","volume":"3","author":"Patoulias","year":"2021","journal-title":"Kidney Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.xkme.2020.10.008","article-title":"Acute kidney injury associated with semaglutide.","volume":"3","author":"Leehey","year":"2021","journal-title":"Kidney Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports.","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.7150\/thno.95796","article-title":"ISG15 accelerates acute kidney injury and the subsequent AKI-to-CKD transition by promoting TGF\u03b2R1 ISGylation.","volume":"14","author":"Cui","year":"2024","journal-title":"Theranostics."},{"key":"B41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000525561","article-title":"Facing the challenge of drug-induced acute interstitial nephritis.","volume":"147","author":"Sanchez-Alamo","year":"2023","journal-title":"Nephron."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/aje\/kwac021","article-title":"Glucagon-Like Peptide 1 receptor agonists and risk of anaphylactic reaction among patients with Type 2 diabetes: a multisite population-based cohort study.","volume":"191","author":"Pradhan","year":"2022","journal-title":"Am J Epidemiol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1793349\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:19:05Z","timestamp":1780287545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1793349\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":42,"alternative-id":["10.3389\/fmed.2026.1793349"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1793349","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"1793349"}}